pharmaphorum Top Stories - 7th October

Last week the FDA declared that shortages of tirzepatide have come to an end – welcome news at a crucial time in the competitive landscape of GLP-1 therapies.

Also in the top stories covered was news that Amgen is to face an investor lawsuit over a $10.7bn tax liability disclosure, while Johnson & Johnson's stand against 340B abuse and duplicate discounts came to a halt in the face of HRSA threats of termination.

More positively, Gilead Sciences signed royalty-free voluntary licensing agreements with six generic manufacturers, paving the way for increased production and distribution of lenacapavir, its long-acting HIV prevention medication, and Blue Shield bypassed PBMs to slash Humira prices by 90%.

Catch up below and at pharmaphorum.com!

Top Stories

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro. READ MORE

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant. READ MORE

Gilead strikes deal to expand HIV drug access in 120 countries

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers. READ MORE

Blue Shield of California bypasses PBMs to slash Humira prices by 90%

Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the price of Humira by up to 90%. READ MORE

J&J's 340B rebate scheme stymied by strong-arm HRSA letter

Johnson & Johnson's stand against 340B abuse and duplicate discounts came to a halt in the face of HRSA threats of termination. READ MORE

Discover how to balance personalised engagement with regulatory compliance across global pharma markets in an upcoming webinar presented by EVERSANA INTOUCH.

Join industry leader Denise Dalton, VP of worldwide omnichannel strategy at Bristol Myers Squibb, as she explores the challenges of achieving personalisation at scale in today's interconnected pharmaceutical landscape. REGISTER FOR THIS EVENT

ON DEMAND WEBINARS

Beyond clinical: Boosting recruitment and retention with SDOH data WATCH NOW

Shifting the paradigm in pharma marketing with content transformation WATCH NOW

Unlocking the Power of Storytelling in Medical Publications WATCH NOW